The Europe in-vitro diagnostics market is expected to grow from US$ 22,616.55 million in 2022 to US$ 34,247.12 million by 2030. It is estimated to grow at a CAGR of 5.3% from 2022 to 2030.
Market Introduction
In-vitro diagnostics (IVDs), including immunoassays and molecular assays, play a crucial role in diagnosing infectious diseases. Diagnostic companies have rapidly accelerated their offerings to manage COVID-19, while regulatory authorities temporarily adjusted their standards, facilitating the launch of new IVDs during the pandemic. These government initiatives led to a surge in demand for molecular diagnostics and immunoassays. Additionally, many companies expanded their IVD manufacturing product lines.
For instance, in June 2021, the British In Vitro Diagnostics Association (BIVDA) launched its “The Digital Revolution” strategy to foster breakthroughs in in-vitro diagnostics during the COVID-19 pandemic. A year later, in July 2022, BioGX announced the CE-marked launch of a three-gene point-of-care (POC) multiplex COVID-19 test on its Pixel platform. Ultimately, the COVID-19 pandemic significantly boosted the in-vitro diagnostics market due to increased demand for both POC diagnostics and traditional laboratory testing procedures.
Download our Sample PDF Report
@ https://www.businessmarketinsights.com/sample/TIPRE00022122
Europe In-Vitro Diagnostics Market Overview
The European in-vitro diagnostics market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. This regional market’s growth is driven by increasing awareness of disease diagnosis, a growing aging population, and technological advancements in in-vitro diagnostics. Germany holds the largest share of the European IVD market, recognized for its innovation capabilities, benefiting from developments in molecular biology, miniaturization, and automation. The German “Industrie 4.0” project is actively digitizing, particularly in IVD, with “Lab 4.0” focusing on data handling and cloud-based solutions.
The COVID-19 pandemic saw a significant surge in demand for IVDs in Germany, as comprehensive testing was a core component of the German government’s health policy to combat the pandemic. German companies are proven innovators in developing molecular tests, as well as high-tech instruments and consumables for the bioanalysis of molecular information. Furthermore, advancements in in-vitro diagnostics, spurred by innovative product launches and the integration of automation systems in labs, are further boosting the in-vitro diagnostics market in Germany.
Europe In-Vitro Diagnostics Market Segmentation
The Europe in-vitro diagnostics market is segmented into product & services, technology, application, end user, and country.
Based on product & services, the Europe in-vitro diagnostics market is segmented into reagents & kits, instruments, and software & services. The reagents & kits segment held the largest share of the Europe in-vitro diagnostics market in 2022.
Based on technology, the Europe in-vitro diagnostics market is segmented into immunoassay/ immunochemistry, clinical chemistry, molecular diagnostics, microbiology, blood glucose self-monitoring, coagulation & hemostasis, hematology, urinalysis, and others. The immunoassay/ immunochemistry segment held the largest share of the Europe in-vitro diagnostics market in 2022.
Based on application, the Europe in-vitro diagnostics market is segmented into infectious diseases, diabetes, oncology, cardiology, autoimmune diseases, nephrology, and others. The infectious diseases segment held the largest share of the Europe in-vitro diagnostics market in 2022.
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications
